Extension Letter to International Assignment Agreement between Teva Pharmaceuticals Europe and Richard Daniell
Teva Pharmaceuticals Europe and Richard Daniell have agreed to extend Richard Daniell's international assignment, originally set by an agreement dated March 7, 2017, until March 15, 2024. All original terms and conditions remain unchanged during this extension. Teva retains the right to terminate the extension at any time for any reason. Both parties have signed to confirm their acceptance of these terms.
Exhibit 10.24
Private and confidential
February 9, 2022
To: Richard Daniell
Subject: Extension letter to International Assignment Agreement dated
March 7, 2017 (the “Agreement”)
The parties mutually agree to extend the undersigned international assignment until March 15, 2024 (the “Extension Period”).
All terms and conditions under the Agreement will remain the same during the Extension Period.
The Extension Period may be terminated by Teva at any time and for any reason.
Sincerely Yours,
| /s/ Niel Hoskings | 11-Feb-2022 |
Niel Hoskings
SVP, HRBP
Teva Pharmaceuticals Europe
Please indicate your agreement by signing below and returning this letter as soon as possible.
I have reviewed the terms of this Extension Period outlined above and by signing below, accept those terms.
| Richard Daniell | /s/ Richard Daniell | February 11, 2022 | ||||||
| Name | Signature | Date |
